Investigating the role of CD9 gene regulation in childhood leukemia relapses
REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
This study looks at how the CD9 gene might affect relapses in children with B-acute lymphoblastic leukemia to help find better ways to diagnose and treat the disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 0 Years to 17 Years |
| Sex | All |
| Sponsor | Rennes University Hospital Academic / other |
| Locations | 3 sites (Angers and 2 other locations) |
| Trial ID | NCT06649253 on ClinicalTrials.gov |
What this trial studies
This project focuses on B-acute lymphoblastic leukaemia (B-ALL), the most common cancer in children, particularly examining the role of the CD9 gene in patient relapses. The study involves collecting bone and blood samples from newly diagnosed patients at three critical points during their treatment. Researchers aim to understand how non-coding RNAs regulate CD9 expression, which may serve as a marker for potential relapses. If successful, this could lead to new diagnostic and therapeutic strategies for managing B-ALL.
Who should consider this trial
Good fit: Ideal candidates for this study are children under 18 years old with a confirmed diagnosis of B-ALL.
Not a fit: Patients with isolated extramedullary involvement or those under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new diagnostic and prognostic markers for predicting relapses in pediatric B-ALL patients.
How similar studies have performed: While the specific approach of targeting CD9 regulation in B-ALL is novel, similar studies have shown promise in understanding gene regulation in cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Under 18 years * With established diagnosis of B-ALL * Initial diagnosis made in the investigating centre * Having received oral and written information about the protocol, or oral only if the patient is unable to read. * Having signed a consent form if the patient is capable of giving informed written consent. * Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent. * Beneficiary of a social security scheme Exclusion Criteria: * Isolated extramedullary involvement at inclusion * Patient of childbearing age without effective contraception. * Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Where this trial is running
Angers and 2 other locations
- CHU Angers — Angers, France (Recruiting)
- CHU Brest — Brest, France (Recruiting)
- CHU Rennes — Rennes, France (Recruiting)
Study contacts
- Study coordinator: Elie COUSIN, Md
- Email: elie.cousin@univ-rennes.fr
- Phone: 299284321
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.